Trial Profile
An Investigator Initiated Study to Evaluate the Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions In Healthy Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Allergic contact dermatitis
- Focus Therapeutic Use
- 04 Dec 2023 Status changed from recruiting to completed.
- 27 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 06 Apr 2021 Planned End Date changed from 1 Nov 2021 to 1 Dec 2022.